Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 472,941 | 560,005 | 635,365 | 690,937 | 269,928 |
| Receivables | 1,876 | 2,417 | 5,503 | 1,029 | 1,421 |
| TOTAL | $507,372 | $589,047 | $665,770 | $710,776 | $291,177 |
| Non-Current Assets | |||||
| PPE Net | 671 | 565 | 462 | 376 | 304 |
| Other Non-Current Assets | 7,664 | 66 | 133 | 294 | 589 |
| TOTAL | $8,335 | $631 | $595 | $670 | $893 |
| Total Assets | $515,707 | $589,678 | $666,365 | $711,446 | $292,070 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 20,727 | 11,035 | 7,170 | 3,910 | 7,511 |
| Accrued Expenses | 45,879 | 33,914 | 41,300 | 27,886 | 32,134 |
| TOTAL | $66,653 | $45,018 | $48,608 | $32,102 | $40,259 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $66,653 | $45,018 | $48,608 | $32,102 | $40,259 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 146,785 | 146,367 | 146,054 | 145,293 | 144,662 |
| Common Shares | 14 | 14 | 14 | 14 | 13 |
| Retained earnings | -1,021,952 | -912,833 | -825,683 | -750,364 | -698,946 |
| Other shareholders' equity | 1,910 | 1,820 | 1,908 | -600 | 513 |
| TOTAL | $449,054 | $544,660 | $617,757 | $679,344 | $251,811 |
| Total Liabilities And Equity | $515,707 | $589,678 | $666,365 | $711,446 | $292,070 |